OpenAI Restricts Astra AI Over Cyberattack Risks 
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium 
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
DHL Q2 Profit Jumps 24% as Express Business Drives Growth 
Meta AI Model Exploits Security Flaw During Cybersecurity Test, Raising AI Safety Concerns 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
UK AI Security Tests Reveal Anthropic and OpenAI Agents Attempted Unauthorized Actions 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
SpaceX Targets Starship Flight 14 With First V3 Starlink Satellite Launch 
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 
BRIDGEWATER, N.J., March 06, 2018 -- Clinical Genomics, a leading provider of colorectal cancer testing and solutions, is pleased to announce that its CLIA licensed and CAP accredited New Jersey laboratory is now licensed by the Florida Agency for Healthcare Administration to offer services for patients residing within the state of Florida. Clinical Genomics is the sole provider of COLVERA™, a liquid biopsy ctDNA assay used to detect residual disease and recurrent disease in patients previously diagnosed with colorectal cancer.
Dr. Lawrence LaPointe, President and CEO of Clinical Genomics, said, “This approval allows Florida doctors to offer COLVERA to their patients in one of the largest US oncology markets.”
“We are pleased to make available our world-class liquid biopsy testing to colorectal cancer surgeons and medical oncologists for the nearly 10,000 patients in Florida who are treated for colorectal cancer each year,” added Dr. John P. Alsobrook II, DABCC, FACB, Laboratory Site Director and Vice President of Operations for Clinical Genomics Pathology.
About Clinical Genomics
Clinical Genomics is dedicated to improving patient outcomes through early detection of colorectal cancer. Clinical Genomics products span the full spectrum of colorectal cancer testing, including InSure® FIT™, a fecal immunochemical test for screening in healthy adults, InSure® ONE™, a one sample FIT used to detect lower GI bleeding, and COLVERA™, a proprietary liquid biopsy blood test identifying circulating tumor DNA for detection of residual disease and early detection of recurrence in post-treatment patients. Clinical Genomics is committed to developing and delivering solutions that provide physicians and their patients with information to help guide earlier and better treatment decisions in cancer care management. Clinical Genomics continues to apply its proprietary innovation in molecular pathology to commercialize other diagnostic tools in other cancer types.
Media Contact:
Patty Jenkins
[email protected]
+ 1.412.376. 2770
